Health X Healthcare Network Posts Rs 28.74 Crore Half-Year Loss

Health X Platform Limited reported a Rs 28.7402 crore Healthcare Network loss before finance costs and tax for the half year ended September 30, 2026, despite segment revenue of Rs 31.3979 crore. The loss was Rs 0.1991 crore higher than the Rs 28.5411 crore loss reported for the corresponding half year ended September 30, 2025.

Why did Health X report a healthcare operating loss?

Health X reported a Rs 28.7402 crore Healthcare Network loss before finance costs and tax in the half year ended September 30, 2026. This is the segment-result measure disclosed by the company, rather than a segment net loss after tax, and it compares with a Rs 28.5411 crore loss in the corresponding 2025 half year.

The Healthcare Network generated Rs 31.3979 crore of revenue during the six-month period, while the corresponding prior-year half-year segment-revenue column shows no reported revenue. The disclosed figures indicate that revenue was insufficient to offset costs captured in the segment result for the period.

Health X defines the Healthcare Network as pathology activities and trading and distribution of healthcare, fast-moving consumer goods and pharmaceutical products through an e-commerce platform. It also includes diagnostic services comprising pathological and non-pathological investigations, meaning the Rs 28.7402 crore loss covers multiple healthcare activities.

The full-year comparison shows that Healthcare Network revenue was Rs 22.7689 crore in the year ended March 31, 2026, while its segment loss was Rs 66.6326 crore. The Rs 28.7402 crore loss in the first half of 2026-27 was below that preceding full-year figure, but Health X provided no second-half forecast or break-even target.

How did Health X healthcare performance change quarter to quarter?

Health X recorded a Rs 13.8707 crore Healthcare Network loss before finance costs and tax in the quarter ended September 30, 2026, compared with a Rs 14.8695 crore loss in the quarter ended June 30, 2026. The sequential loss narrowed by Rs 0.9988 crore, although both quarterly segment results remained negative.

Healthcare Network revenue was Rs 28.836 crore in the September 2026 quarter, up from Rs 28.5143 crore in the June 2026 quarter. The Rs 0.3217 crore sequential increase in revenue coincided with the reduction in loss, but the filing does not give a separate cost bridge for the change.

Against the quarter ended September 30, 2025, the September 2026 Healthcare Network loss narrowed from Rs 15.8534 crore to Rs 13.8707 crore. The improvement was Rs 1.9827 crore, while the comparable prior-year quarter shows no Healthcare Network revenue in the segment table.

The six-month pattern reflects a larger September-quarter revenue contribution, with Rs 28.836 crore of the Rs 31.3979 crore half-year revenue reported in that quarter. The filing does not state whether this concentration arose from pathology, diagnostic services, e-commerce distribution or another part of the Healthcare Network.

How large is Health X healthcare business on the balance sheet?

Health X reported Healthcare Network assets of Rs 768.1012 crore as at September 30, 2026, compared with Rs 126.9882 crore in Financial Services assets. The Healthcare Network therefore represented the largest reported operating segment by assets within total consolidated assets of Rs 945.3129 crore.

Healthcare Network assets fell from Rs 846.6906 crore at September 30, 2025 and Rs 771.3718 crore at March 31, 2026 to Rs 768.1012 crore at September 30, 2026. The six-month reduction from the March 2026 balance was Rs 3.2706 crore, while the year-on-year reduction was Rs 76.5894 crore.

Healthcare Network liabilities stood at Rs 183.7362 crore at September 30, 2026, up from Rs 163.4382 crore at March 31, 2026 and Rs 124.0586 crore a year earlier. Financial Services liabilities were Rs 5.4295 crore, while total segment liabilities were Rs 190.5104 crore at the September 2026 reporting date.

The balance-sheet figures sit alongside a Rs 28.7402 crore Healthcare Network loss for the first half of 2026-27. Health X does not provide a segment-level reconciliation identifying how individual asset classes, such as inventory, property or receivables, contributed to the healthcare result.

What does Health X disclose about its healthcare operations?

Health X says Genu Path Labs Limited, a step-down subsidiary, began operations in diagnostics and healthcare services in 2018. The company states that initiatives to develop its service network and physical presence did not produce expected outcomes, resulting in operational losses.

The auditor drew attention to a material uncertainty relating to going concern at Genu Path Labs because its net worth has been completely eroded. Health X nevertheless prepared the subsidiary’s financial statements on a going-concern basis after Sastasundar Healthbuddy Limited assured continued financial support for revised strategies intended to revive and strengthen the business.

The filing does not quantify Genu Path Labs’ individual contribution to the Healthcare Network’s Rs 28.7402 crore half-year loss. It does disclose an impairment loss of Rs 16.61 lakh related to Genu Path Labs as an exceptional item in the quarter and half year ended September 30, 2025, followed by a net Rs 5.93 lakh impairment for the year ended March 31, 2026.

Health X’s segment disclosure also shows a contrast with Financial Services, which recorded a Rs 0.1644 crore loss before finance costs and tax in the half year ended September 30, 2026. Financial Services had reported a Rs 12.1424 crore profit in the corresponding 2025 half year, while the Healthcare Network loss increased by Rs 0.1991 crore over the same comparison.

Conclusion

Health X’s September 2026 half-year results show that Healthcare Network revenue of Rs 31.3979 crore had not translated into segment profitability, with a Rs 28.7402 crore loss before finance costs and tax. The September-quarter loss narrowed from the June quarter, but the segment’s liabilities increased from Rs 163.4382 crore at March 31, 2026 to Rs 183.7362 crore at September 30, 2026.

The next disclosed matter to watch is the implementation of revised strategies at Genu Path Labs, which remains on a going-concern basis with financial support from Sastasundar Healthbuddy Limited. Health X’s board also approved a composite scheme of arrangement and amalgamation on June 10, 2026, but the company had recorded no accounting effect in the September 2026 results pending approvals.